What’s Next? Five Things To Look Out For In February
Accord Plans To Roll Out Generic Revlimid In More European Markets
In February, key launches from Accord and Eagle are set to go ahead, while Viatris will host its delayed investor day and industry will meet in-person in Florida for the US Association for Accessible Medicines’ Access! event.
You may also be interested in...
Accord has confirmed the launch of a generic lenalidomide rival to Revlimid in the UK. The launch leads off a year that is expected to see the BMS blockbuster also face significant competition elsewhere in Europe and the US.
With Eagle set to launch its long-awaited vasopressin ANDA product on 17 January, the US firm’s management told investors it was unsure what its launch meant for the 505(b)(2) rival product in the hands of American Regent.
After being found liable for helping fuel the opioid epidemic in New York last month, Teva used the J.P. Morgan Healthcare Conference to explain how it intends to go about overturning the verdict.